Dr. Guminski on 16-Month Follow-Up With Cemiplimab in mCSCC

Video

Alexander Guminski, MD, PhD, medical oncologist, Royal North Shore Hospital, University of Sydney, discusses the 16-month follow-up results of a phase II trial evaluating cemiplimab (Libtayo) in patients with metastatic cutaneous squamous cell carcinoma.

Alexander Guminski, MD, PhD, medical oncologist, Royal North Shore Hospital, University of Sydney, discusses the 16-month follow-up results of a phase II trial evaluating cemiplimab (Libtayo) in patients with metastatic cutaneous squamous cell carcinoma.

In a primary analysis reported in October 2017, cemiplimab, a human monoclonal anti-PD-1 agent, demonstrated significant antitumor activity, response rates, and promising safety. In the trial, 59 patients were given 3 mg/kg of cemiplimab intravenously every 2 weeks. Tumors were measured every 8 weeks to evaluate overall response rate (ORR), which served as the primary endpoint of the trial. More than half the patients had one or more prior lines of systemic treatment, while three-fourths of patients had distant visceral metastatic disease.

At a median follow-up of 16 months, Guminski reports that there was slight improvement in ORR as the data has matured. Specifically, an ORR of 49% was reported, with 17% of that group achieving a complete response to the treatment.

Related Videos
Samilia Obeng-Gyasi, MD, MPH
Tycel Phillips, MD
Ajai Chari, MD
Reshma Jagsi, MD, DPhil, Emory University
Nisha A. Mohindra, MD, Northwestern University Feinberg School of Medicine
Katrina S. Pedersen, MD, MS, associate professor, John T. Milliken Department of Medicine, Division of Oncology, Medical Oncology program leader, cofounder, Young Onset Colorectal Cancer Program, Washington University School of Medicine in St. Louis, Siteman Cancer Center
Dan S. Childs, MD, medical oncologist, Mayo Clinic
Neal Shore, MD, FACS, discusses current and ongoing research with radioligand therapy in patients with nonmetastatic castration-sensitive prostate cancer.
Jane L. Meisel, MD